Cisapride (R 51619): Nonselective 5-HT4 Agonist & hERG Inhibitor in Cardiac Electrophysiology Research

Executive Summary: Cisapride (R 51619) is a chemically defined, nonselective 5-HT4 receptor agonist used in cardiac and gastrointestinal research (APExBIO, product page). It is a potent inhibitor of the human ether-à-go-go-related gene (hERG) potassium channel, making it a reference compound in studies of drug-induced arrhythmogenicity (Grafton et al., 2021). High-content phenotypic screening with iPSC-derived cardiomyocytes has confirmed its utility for early cardiotoxicity detection (Grafton et al., 2021). The compound is supplied at 99.70% purity with full analytical documentation by APExBIO. It demonstrates robust solubility in DMSO (≥23.3 mg/mL) and ethanol (≥3.47 mg/mL), but is insoluble in water, necessitating careful workflow integration (APExBIO).

Biological Rationale

Cisapride (R 51619) is structurally characterized as 4-amino-5-chloro-N-[1-[3-(4-fluorophenoxy)propyl]-3-methoxypiperidin-4-yl]-2-methoxybenzamide, with a molecular weight of 465.95 g/mol (APExBIO). Its pharmacological profile includes nonselective agonism at 5-HT4 receptors and potent inhibition of the cardiac hERG potassium channel. These dual activities underpin its use in research focused on gastrointestinal motility and cardiac electrophysiology (see related review). In particular, hERG channel inhibition is a major mechanism for drug-induced long QT syndrome and arrhythmias, making Cisapride a key benchmark compound in preclinical cardiotoxicity studies (Grafton et al., 2021). 5-HT4 receptor activation is relevant for studies of gastrointestinal motility and neuronal signaling, expanding the compound's utility beyond cardiac models (complementary mechanistic analysis).

Mechanism of Action of Cisapride (R 51619)

Cisapride binds to and activates 5-HT4 receptors, which are G protein-coupled and mediate cAMP-dependent signaling cascades in neurons and smooth muscle (Grafton et al., 2021). This agonism increases acetylcholine release, enhancing gastrointestinal motility. Simultaneously, Cisapride blocks the hERG (KCNH2) potassium channel, inhibiting the rapid delayed rectifier potassium current (I_Kr) critical for cardiac repolarization. The blockade can cause prolonged QT intervals and predispose cells to arrhythmogenic events—making hERG inhibition a gold-standard phenotype for preclinical cardiotoxicity screening (see advanced workflow integration). These dual mechanisms distinguish Cisapride from other serotonergic agents and are central to its scientific applications.

Evidence & Benchmarks

• Cisapride induces dose-dependent QT prolongation in human iPSC-derived cardiomyocytes, replicating clinical arrhythmia phenotypes (Grafton et al., 2021).
• As a nonselective 5-HT4 agonist, Cisapride elicits increased gastrointestinal motility in ex vivo tissue models (APExBIO, product documentation).
• It is highly soluble in DMSO (≥23.3 mg/mL) and ethanol (≥3.47 mg/mL), but insoluble in water, influencing experimental design and assay compatibility (APExBIO).
• High-content phenotypic screens using deep learning algorithms robustly identify Cisapride as a cardiotoxic agent in iPSC-CMs, validating its predictive power for preclinical safety assessment (Grafton et al., 2021).
• Quality control with HPLC, NMR, and MSDS ensures batch-to-batch reproducibility and >99.7% purity, supporting experimental reliability (APExBIO).

Applications, Limits & Misconceptions

Cisapride is widely employed in the following research contexts:

• Cardiac electrophysiology: Benchmarking hERG channel blockers and modeling drug-induced arrhythmias.
• 5-HT4 receptor signaling: Probing serotonergic pathways in neuronal and gastrointestinal tissues.
• Phenotypic screening: Validating deep learning or high-content imaging pipelines for cardiotoxicity using iPSC-derived cardiomyocytes (explore deep phenotyping tools).
• Translational safety pharmacology: Early de-risking of candidate drugs by comparison against a well-characterized reference inhibitor (Grafton et al., 2021).

Common Pitfalls or Misconceptions

• Not selective for 5-HT4: Cisapride is a nonselective 5-HT4 agonist and may affect other serotonergic receptors at higher concentrations.
• Water insolubility: Attempting to dissolve Cisapride in water leads to incomplete solubilization and unreliable dosing.
• Long-term solution storage: Solution forms are unstable over time, especially at room temperature; store at -20°C and use fresh preparations.
• Clinical extrapolation: Findings in preclinical systems (e.g., iPSC-derived cardiomyocytes) may not fully predict in vivo human cardiac risk without dose/exposure matching.
• Batch variability: Using unverified sources can introduce impurities that confound assay results; APExBIO provides full QC to mitigate this risk.

Workflow Integration & Parameters

Cisapride (SKU B1198) from APExBIO is typically supplied as a solid and should be dissolved in DMSO or ethanol for cell-based assays. For optimal stability, aliquots should be stored at -20°C and used within one month of preparation. Solutions exceeding 23.3 mg/mL (DMSO) or 3.47 mg/mL (ethanol) are achievable. It is recommended to avoid repeated freeze-thaw cycles and to prepare working dilutions immediately before use (see best practices Q&A). When benchmarking hERG inhibition, apply concentrations aligned with those validated in iPSC-CM assays (e.g., 100 nM–10 µM) and include appropriate vehicle controls (Grafton et al., 2021). For high-content phenotypic screens, ensure compatibility with DMSO or ethanol vehicle and monitor for solvent effects. Analytical documentation (HPLC, NMR, MSDS) is provided with each lot to assure quality and reproducibility.

Conclusion & Outlook

Cisapride (R 51619) remains a reference standard in preclinical cardiac safety and 5-HT4 signaling research. Its dual action as a nonselective 5-HT4 agonist and potent hERG potassium channel inhibitor enables researchers to dissect arrhythmogenic mechanisms and validate predictive assay platforms. Stable supply from APExBIO, with high purity and full analytical support, facilitates robust experimental workflows. As phenotypic screening and iPSC-derived assays advance, Cisapride will continue to serve as a critical benchmark for translational cardiotoxicity and gastrointestinal motility studies.